Durvalumab (Imfinzi)
Dilution requiredFull monograph review pending
U.S. label preparation
Imfinzi · Dilution required
- Preparation
- Dilute IV durvalumab to 1 to 15 mg/mL with 0.9% sodium chloride or 5% dextrose. Invert gently and discard residual vial contents.
- Administration and handling
- Infuse over 60 minutes using the sterile low protein-binding filter specified in section 2.4. Check drug sequence and intervals for combination regimens.
Product and source details
AstraZeneca Pharmaceuticals LP · BLA761069
Product NDC: 0310-4500, 0310-4611
SPL effective 2026-08-31 | SPL version 34. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.